These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9298962

  • 1. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
    Dunham SU, Lippard SJ.
    Biochemistry; 1997 Sep 23; 36(38):11428-36. PubMed ID: 9298962
    [Abstract] [Full Text] [Related]

  • 2. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE, Zamble DB, Lippard SJ, Essigmann JM.
    Biochemistry; 1998 Jan 06; 37(1):352-62. PubMed ID: 9425057
    [Abstract] [Full Text] [Related]

  • 3. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ.
    Nature; 1999 Jun 17; 399(6737):708-12. PubMed ID: 10385126
    [Abstract] [Full Text] [Related]

  • 4. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM, Mikata Y, He Q, Lippard SJ.
    Biochemistry; 2000 Sep 26; 39(38):11771-6. PubMed ID: 10995245
    [Abstract] [Full Text] [Related]

  • 5. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA, Lippard SJ.
    Biochemistry; 1996 Feb 20; 35(7):2180-8. PubMed ID: 8652559
    [Abstract] [Full Text] [Related]

  • 6. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM, Whitehead JP, Raju NL, Lippard SJ.
    Biochemistry; 1997 Dec 02; 36(48):14807-15. PubMed ID: 9398202
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
    Turchi JJ, Li M, Henkels KM.
    Biochemistry; 1996 Mar 05; 35(9):2992-3000. PubMed ID: 8608137
    [Abstract] [Full Text] [Related]

  • 8. LEF-1 recognition of platinated GG sequences within double-stranded DNA. Influence of flanking bases.
    Chválová K, Sari MA, Bombard S, Kozelka J.
    J Inorg Biochem; 2008 Feb 05; 102(2):242-50. PubMed ID: 17961652
    [Abstract] [Full Text] [Related]

  • 9. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM, Whitehead JP, Lippard SJ.
    Biochemistry; 1996 May 14; 35(19):6089-99. PubMed ID: 8634251
    [Abstract] [Full Text] [Related]

  • 10. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
    Locker D, Decoville M, Maurizot JC, Bianchi ME, Leng M.
    J Mol Biol; 1995 Feb 17; 246(2):243-7. PubMed ID: 7869375
    [Abstract] [Full Text] [Related]

  • 11. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link on the conformational and thermodynamic properties of duplex DNA.
    Pilch DS, Dunham SU, Jamieson ER, Lippard SJ, Breslauer KJ.
    J Mol Biol; 2000 Feb 25; 296(3):803-12. PubMed ID: 10677282
    [Abstract] [Full Text] [Related]

  • 12. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS, Barnes CM, Lippard SJ.
    Biochemistry; 1995 Mar 07; 34(9):2956-64. PubMed ID: 7893709
    [Abstract] [Full Text] [Related]

  • 13. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
    Kasparkova J, Delalande O, Stros M, Elizondo-Riojas MA, Vojtiskova M, Kozelka J, Brabec V.
    Biochemistry; 2003 Feb 11; 42(5):1234-44. PubMed ID: 12564926
    [Abstract] [Full Text] [Related]

  • 14. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ.
    Nature; 1995 Oct 19; 377(6550):649-52. PubMed ID: 7566180
    [Abstract] [Full Text] [Related]

  • 15. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG.
    Biochemistry; 1999 Aug 24; 38(34):11026-39. PubMed ID: 10460158
    [Abstract] [Full Text] [Related]

  • 16. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
    Jung Y, Lippard SJ.
    Biochemistry; 2003 Mar 11; 42(9):2664-71. PubMed ID: 12614161
    [Abstract] [Full Text] [Related]

  • 17. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.
    Gelasco A, Lippard SJ.
    Biochemistry; 1998 Jun 30; 37(26):9230-9. PubMed ID: 9649303
    [Abstract] [Full Text] [Related]

  • 18. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez JM, Brabec V.
    Chem Res Toxicol; 2003 Nov 30; 16(11):1424-32. PubMed ID: 14615968
    [Abstract] [Full Text] [Related]

  • 19. Recognition of cisplatin-DNA interstrand cross-links by replication protein A.
    Patrick SM, Tillison K, Horn JM.
    Biochemistry; 2008 Sep 23; 47(38):10188-96. PubMed ID: 18729380
    [Abstract] [Full Text] [Related]

  • 20. Nucleotide excision repair from site-specifically platinum-modified nucleosomes.
    Wang D, Hara R, Singh G, Sancar A, Lippard SJ.
    Biochemistry; 2003 Jun 10; 42(22):6747-53. PubMed ID: 12779329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.